查看中文
The Stock Exchange of Hong Kong Limited (HKEX) and Securities and Futures Commission (SFC) have announced a temporary relaxation of the minimum market capitalization requirements for Specialist Technology Company...more
8/30/2024
/ Capital Markets ,
Corporate Governance ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Listing Rules ,
Popular ,
Private Investment in Public Equity (PIPEs) ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)
With deep and liquid capital markets offering unique access to the Mainland China investor market, many international businesses are considering pursuing their IPOs in Hong Kong. This summary outlines key issues for companies...more
6/18/2024
/ Acquisitions ,
Asia Pacific ,
Capital Markets ,
China ,
Disclosure Requirements ,
Financial Services Industry ,
Global Market ,
Hong Kong ,
Initial Public Offering (IPO) ,
Intellectual Property Protection ,
Investment ,
Listing Rules ,
Mergers ,
Registration Requirement ,
Regulatory Agenda ,
Regulatory Requirements
查看中文
This update provides an overview of key regulatory developments in the fourth quarter of 2023 relevant to companies listed, or planning to list, on The Stock Exchange of Hong Kong Limited (HKEx) and their advisers....more
3/5/2024
/ Board of Directors ,
Capital Markets ,
Corporate Governance ,
Disclosure Requirements ,
Environmental Social & Governance (ESG) ,
Financial Regulatory Reform ,
Foreign Corporations ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Internal Controls ,
Listing Rules ,
Publicly-Traded Companies ,
Regulatory Agenda
查看中文
Following a market consultation process in late 2022, the Stock Exchange of Hong Kong Limited (HKEX) introduced a new regime to permit the listing of companies operating in specified specialist technology sectors....more
点击此处阅读调查报告全文
Our third annual report on Hong Kong-listed biotech companies examines how the sector performed during the challenging conditions for capital markets globally over the past 12 months. Although aggregate listing...more
4/25/2023
/ Biotechnology ,
Capital Markets ,
Capital Raising ,
Corporate Governance ,
Foreign Corporations ,
Healthcare ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Life Sciences ,
Listing Rules ,
Popular ,
Publicly-Traded Companies
With ongoing regulatory developments affecting capital markets globally, many China-related businesses are considering pursuing their IPOs in Hong Kong. However, the regulatory regime for IPOs on the Stock Exchange of Hong...more
Our second annual report on Hong Kong-listed biotech companies demonstrates the continued health of the sector. The report provides a comprehensive overview of the market in its current state, examining key data points for...more
This update provides an overview of key regulatory developments in the past three months relevant to companies listed or planning to list on The Stock Exchange of Hong Kong Limited (HKEx), and their advisers. In particular,...more
10/8/2021
/ Capital Markets ,
Corporate Governance ,
HKEx ,
Hong Kong ,
Hong Kong Securities and Futures Commission (HKSFC) ,
Hong Kong Stock Exchange ,
Initial Public Offering (IPO) ,
Listing Rules ,
Private Investment in Public Equity (PIPEs) ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs)
With ongoing regulatory developments affecting capital markets globally, many China-related businesses are considering pursuing their IPOs in Hong Kong. However, the regulatory regime for IPOs on the Stock Exchange of Hong...more
查看中文 - This update provides an overview of key regulatory developments in the past three months relevant to companies listed, or planning to list, on The Stock Exchange of Hong Kong Limited (HKEx), and their advisers. In...more